贝卡普勒明
| A+医学百科 >> 药品百科 >> 贝卡普勒明 |
贝卡普勒明（Becaplermin），As adjunct to good ulcer care practices to treat lower extremity diabetic neuropathic ulcers that extend into SC tissue or beyond and have adequate blood supply. Use for diabetic neuropathic ulcers that do not extend through dermis into SC tissue or ischemic ulcers has not been studied.
本药品被归类到激素药物等药品分类。
目录 |
贝卡普勒明的副作用（不良反应）
General: Infection, cellulitis, osteomyelitis, erythematous rashes.
服用贝卡普勒明须注意的事项
Pregnancy Category: C
Contraindications: Known neoplasms at application site. Use in wounds that close by primary intention.
Special Concerns: Effect on exposed joints, tendons, ligaments, and bone has not been established. Use with other topical drugs has not been studied. Use with caution during lactation. Safety and efficacy have not been determined in children less than 16 years of age.
贝卡普勒明的用法用量
注意：同种药品可由于不同的包装规格有不同的用法或用量。本文只供参考。如果不确定，请参看药品随带的说明书或向医生询问。
Gel, 0.01% Lower extremity diabetic neuropathic ulcers. Dose depends on size of ulcer area. To determine length of gel to be applied, measure greatest length of ulcer by greatest width of ulcer in either inches or centimeters. To calculate length of gel in inches:7.5 g or 15 g tube: length x width x 0.62 g tube: length x width x 1.3Generally, each square inch of ulcer surface will require about 2/3 inch from 7.5 g or 15 g tube and about 11/4 inches from 2 g tube.To calculate length of gel in centimeters:7.5 g or 15 g tube: length x width divided by 42 g tube: length x width divided by 2Generally, each square centimeter of ulcer surface will require about 0.25 cm of gel from 7.5 or 15 g tube or about 0.5 cm of gel from 2 g tube. Calculate
贝卡普勒明药理作用
Classification: Topical wound healing drug Action/Kinetics: Topical recombinant human platelet-derived growth factor. Promotes chemotactic recruitment and proliferation of cells involved in wound repair and enhances formation of granulation tissue.
市场上的贝卡普勒明
- 贝卡普勒明
参看
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 关于“贝卡普勒明”的留言： |  订阅讨论RSS
|
|
目前暂无留言 | |
| 添加留言 | |